Users online: 2082    [ij] [ij] [ij] 
Email id

ACADEMICIA: An International Multidisciplinary Research Journal
Year : 2020, Volume : 10, Issue : 11
First page : ( 2273) Last page : ( 2280)
Online ISSN : 2249-7137.
Article DOI : 10.5958/2249-7137.2020.01609.2

Efficacy of rosuvastatin and ezetimib combination for diabetic dyslipidemia in patients with type 2 diabetes

Urunbaeva D.A., Akramkhuzhaeva A.B.

Tashkent Medical Academy, Uzbekistan


One of the necessary drugs for the treatment of diabetic dyslipidemia affecting lipid metabolism is hydroxycis-methylglutaryl-coenzyme A-reductase inhibitors (statins) [2] and ezetimibe, which blocks the absorption of cholesterol in the epithelium of the small intestine, thereby preventing erythematic enterohepatic circulation of cholesterol [2,4]. Their effectiveness in correcting atherogenic dyslipidemia (DLP) and preventing macroangiopathieshas been studied in patients with diabetes mellitus (DM). The aim of this study was to study the lipid-lowering efficacy of the combination therapy of rosuvastatin with ezithymibe in patients with type 2 diabetes mellitus



Diabetes Mellitus (DM), Lipid-Lowering Therapy, Rosuvastatin, Ezetimibe, Total Cholesterol (TC), Low Dencity Lipoproteins (LDL), High Dencity Lipoproteins (HDL).


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
469,356,777 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.